{"schema_version":"secwatch.filing_event.v1","accession":"0001079973-26-000291","form_type":"8-K","ticker":"TOI","cik":"0001799191","company_name":"Oncology Institute, Inc.","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.213258+00:00","generated_at":"2026-05-15T13:44:36.333723+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"confidence":"high","headline":"Oncology Institute Q4 revenue up 41.6% to $142M, net loss narrows to $7.5M","bullets":["Q4 2025 revenue $142.0M (+41.6% YoY); gross profit $22.7M (+55.2%).","Net loss narrowed to $7.5M from $13.2M; adj EBITDA improved to $147K from -$7.8M.","FY2025 revenue $502.7M (+27.8%); net loss $60.6M vs $64.7M; adj EBITDA -$12.4M vs -$35.7M.","Added 9 new capitated contracts in CA, FL, NV covering ~260K lives; expanded Elevance, Humana, CarePlus partnerships.","Cash from operations positive $3.2M in Q4; cash balance $33.6M at year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001079973-26-000291","json":"https://secwatch.observer/filing/0001079973-26-000291.json","markdown":"https://secwatch.observer/filing/0001079973-26-000291.md","text":"https://secwatch.observer/filing/0001079973-26-000291.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799191/000107997326000291/0001079973-26-000291-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799191/000107997326000291/toi_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T13:44:36.333723+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}